Jessica Serra | executive |
Mark Foley | executive |
Tobin Schilke | executive |
David Amsellem | analyst |
Stacy Ku | analyst |
Karishma Raghuram | analyst |
Jack Padovano | analyst |
Alana Lelo | analyst |
John Boyle | analyst |
Terence Flynn | analyst |
Navann Ty Dietschi | analyst |
Serge Belanger | analyst |
Charles Wang | analyst |
Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded on Wednesday, February 28, 2024.I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Corporate Communications and ESG for Revance. Please go ahead.
Thank you, operator.
Joining us on the call today from Revance are: Chief Executive Officer, Mark Foley; and Chief Financial Officer, Toby Schilke.During this call, management will make forward-looking statements, including statements related to the impact of our pricing and strategy on DAXXIFY on adoption, expectations and timing related to product adoption and reorders, our product pipeline, consumer needs, preferences and behavior, the benefits and value to us, practices and consumers of our products, including the efficacy, duration and safety of our products, 2024 guidance, cash flow at even, positive adjusted EBITDA, future capital expenditures, funding our business and capital allocation plans.